Background: Submandibular gland transfer has been widely used to prevent postradiation xerostomia in head-and-neck cancers. However, there are still some controversies. Methods: Six databases were searched, data extraction was performed and the risk of bias was assessed by 2 reviewers independently. The meta-analysis was performed using Review Manager, version 5.2. Results: A total of 7 trials (12 articles) and 369 participants were included. Conclusions: The present clinical evidence suggests that submandibular gland transfer might be highly effective to prevent postradiation xerostomia in head-and-neck cancers without serious adverse events. However, more randomized controlled trials are still needed to confirm this conclusion.

Keywords:
Submandibular gland transfer, Postradiation xerostomia, Prevention, Head-and-neck cancer, Meta-analysis
1.
Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2.
Leemans CR, Braakhuis BJ, Brakenhoff RH: The molecular biology of head and neck cancer. Nat Rev Cancer 2011;11:9-22.
3.
Allegra E, Franco T, Domanico R, La Boria A, Trapasso S, Garozzo A: Effectiveness of therapeutic selective neck dissection in laryngeal cancer. ORL 2014;76:89-97.
4.
Castadot P, Lee JA, Geets X, Grégoire V: Adaptive radiotherapy of head and neck cancer. Semin Radiat Oncol 2010;20:84-93.
5.
Bachmann G, Rössler R, Klett R, Rau WS, Bauer R: The role of magnetic resonance imaging and scintigraphy in the diagnosis of pathologic changes of the mandible after radiation therapy. Int J Oral Maxillofac Surg 1996;25:189-195.
6.
Chencharick JD, Mossman KL: Nutritional consequences of radio-therapy of head and neck cancer. Cancer 1983;51:811-815.
7.
Lee N, Puri DR, Blanco AI, Chao KS: Intensity-modulated radiation therapy in head and neck cancers: an update. Head Neck 2007;29:387-400.
8.
Mandel ID: The functions of saliva. J Dent Res 1987;66:623-627.
9.
Vissink A, Panders AK, Gravenmade EJ, Vermey A: The causes and consequences of hyposalivation. Ear Nose Throat J 1988;67:166-168, 173-176.
10.
Guchelaar HJ, Vermes A, Meerwaldt JH: Radiation-induced xerostomia: pathophysiology, clinical course and supportive treatment. Support Care Cancer 1997;5:281-288.
11.
Epstein JB, Emerton S, Kolbinson DA, Le ND, Phillips N, Stevenson-Moore P, et al: Quality of life and oral function following radiotherapy for head and neck cancer. Head Neck 1999;21:1-11.
12.
Dodds MW, Johnson DA, Yeh CK: Health benefits of saliva: a review. J Dent 2005;33:223-233.
13.
Yoshida E, Suzuki J, Ito E, Hosokawa R, Tanda N, Tamahara T, et al: Measuring flow rates of saliva for accurate diagnosis of xerostomia; in Sasaki K, Suzuki O, Takahashi N (eds): Interface Oral Health Science 2011. Tokyo, Springer, 2012, pp 223-225.
14.
Sreebny LM, Schwartz SS: A reference guide to drugs and dry mouth - 2nd edition. Gerodontology 1997;14:33-47.
15.
Nederfors T: Xerostomia and hyposalivation. Adv Dent Res 2000;14:48-56.
16.
Fox PC, Busch K, Baum BJ: Subjective reports of xerostomia and objective measures of salivary gland performance. Am Dent Assoc 1987;115:581-584.
17.
Sreebny LM: Xerostomia: diagnosis, management and clinical complications; in Edgar WM, O'Mullane DM (eds): Saliva and Oral Health. London, Thanet Press, 1996, pp 43-66.
18.
Hochberg MC, Tielsch J, Munoz B, Bandeen-Roche K, West SK, Schein OD: Prevalence of symptoms of dry mouth and their relationship to saliva production in community dwelling elderly: the SEE project. J Rheumatol 1998;25:486-491.
19.
Wolff M, Kleinberg I: Oral mucosal wetness in hypo- and normosalivators. Arch Oral Biol 1998;43:455-462.
20.
Dawes C: How much saliva is enough for avoidance of xerostomia? Caries Res 2004;38:236-240.
21.
Guggenheimer J, Moore PA: Xerostomia etiology, recognition and treatment. J Am Dent Assoc 2003;134:61-69.
22.
Cho MA, Ko JY, Kim YK, Kho HS: Salivary flow rate and clinical characteristics of patients with xerostomia according to its aetiology. J Oral Rehabil 2010;37:185-193.
23.
Wescott WB, Mira JG, Starcke EN, Shannon IL, Thornby JI: Alterations in whole saliva flow rate induced by fractionated radiotherapy. AJR Am J Roentgenol 1978;130:145-149.
24.
Franzén L, Funegård U, Ericson T, Henriksson R: Parotid gland function during and following radiotherapy of malignancies in the head and neck. A consecutive study of salivary flow and patient discomfort. Eur J Cancer 1992;28:457-462.
25.
Chambers MS, Garden AS, Kies MS, Martin JW: Radiation-induced xerostomia in patients with head and neck cancer: pathogenesis, impact on quality of life, and management. Head Neck 2004;26:796-807.
26.
Shannon IL, McCrary BR, Starcke EN: A saliva substitute for use by xerostomic patients undergoing radiotherapy to the head and neck. Oral Surg Oral Med Oral Pathol 1977;44:656-661.
27.
Kwong DL, Pow EH, Sham JS, McMillan AS, Leung LH, Leung WK, et al: Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function. Cancer 2004;101:1584-1593.
28.
Tsang RK, Kwong DL, Ho AC, To VS, Ho WK, Wei WI: Long-term hearing results and otological complications of nasopharyngeal carcinoma patients: comparison between treatment with conventional two-dimensional radiotherapy and intensity-modulated radiotherapy. ORL 2012;74:228-233.
29.
Burlage FR, Roesink JM, Kampinga HH, Coppes RP, Terhaard C, Langendijk JA, et al: Protection of salivary function by concomitant pilocarpine during radiotherapy: a double-blind, randomized, placebo-controlled study. Int J Radiat Oncol Biol Phys 2008;70:14-22.
30.
Berk L: Systemic pilocarpine for treatment of xerostomia. Expert Opin Drug Metab Toxicol 2008;4:1333-1340.
31.
Jha N, Seikaly H, Harris J, Williams D, Sultanem K, Hier M, et al: Phase III randomized study: oral pilocarpine versus submandibular salivary gland transfer protocol for the management of radiation-induced xerostomia. Head Neck 2009;31:234-243.
32.
Wong RK, James JL, Sagar S, Wyatt G, Nguyen-Tân PF, Singh AK, et al: Phase 2 results from radiation therapy oncology group study 0537: a phase 2/3 study comparing acupuncture-like transcutaneous electrical nerve stimulation versus pilocarpine in treating early radiation-induced xerostomia. Cancer 2012;118:4244-4252.
33.
Blom M, Dawidson I, Fernberg JO, Johnson G, Angmar-Månsson B, et al: Acupuncture treatment of patients with radiation-induced xerostomia. Eur J Cancer B Oral Oncol 1996;32B:182-190.
34.
Johnstone PA, Peng YP, May BC, Inouye WS, Niemtzow RC: Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies. Int J Radiat Oncol Biol Phys 2001;50:353-357.
35.
Koukourakis MI: Amifostine in clinical oncology: current use and future applications. Anticancer Drugs 2002;13:181-209.
36.
Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, et al: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000;18:3339-3345.
37.
Jha N, Seikaly H, McGaw T, Coulter L: Submandibular salivary gland transfer prevents radiation-induced xerostomia. Int J Radiat Oncol Biol Phys 2000;46:7-11.
38.
Seikaly H, Jha N, McGaw T, Coulter L, Liu R, Oldring D: Submandibular gland transfer: a new method of preventing radiation-induced xerostomia. Laryngoscope 2001;111:347-352.
39.
Saltaji H, Major MP, Altalibi M, Youssef M, Flores-Mir C: Long-term skeletal stability after maxillary advancement with distraction osteogenesis in cleft lip and palate patients. Angle Orthod 2012;82:1115-1122.
40.
Lefebvre C, Manheimer E, Glanville J: Searching for studies; in Higgins JPT, Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions. Chichester, Wiley, 2008, pp 7.1-7.28.
41.
Sterne JAC, Egger M, Moher D: Addressing reporting biases; in Higgins JPT, Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions. Chichester, Wiley, 2008, pp 10.1-10.33.
42.
Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-1101.
43.
Jha N, Seikaly H, Harris J, Williams D, Liu R, McGaw T, et al: Prevention of radiation induced xerostomia by surgical transfer of submandibular salivary gland into the submental space. Radiother Oncol 2003;66:283-289.
44.
Seikaly H, Jha N, Harris JR, Barnaby P, Liu R, Williams D, et al: Long-term outcomes of submandibular gland transfer for prevention of postradiation xerostomia. Arch Otolaryngol Head Neck Surg 2004;130:956-961.
45.
Jha N, Harris J, Seikaly H, Jacobs JR, McEwan AJ, Robbins KT, et al: A phase II study of submandibular gland transfer prior to radiation for prevention of radiation-induced xerostomia in head-and-neck cancer (RTOG 0244). Int J Radiat Oncol Biol Phys 2012;84:437-442.
46.
Rieger JM, Jha N, Lam Tang JA, Harris J, Seikaly H: Functional outcomes related to the prevention of radiation-induced xerostomia: oral pilocarpine versus submandibular salivary gland transfer. Head Neck 2012;34:168-174.
47.
Liu XK, Su Y, Jha N, Hong MH, Mai HQ, Fan W, et al: Submandibular salivary gland transfer for the prevention of radiation-induced xerostomia in patients with nasopharyngeal carcinoma: 5-year outcomes. Head Neck 2011;33:389-395.
48.
Liu X, Guo Z, Su Y, Mai H, Hong M, Cui N, et al: Oncological safety evaluation of submandibular salivary gland transfer prevents radiation-induced xerostomia in the patients with nasopharyngeal carcinoma. Chin J Cancer Prevent Treatment 2009;16:1804-1807.
49.
Liu X, Guo Z, Su Y, Hong M, Cui N, Zeng Z: Long-term effect of submandibular salivary gland transfer on radiation-induced xerostomia in patients with nasopharyngeal carcinoma. Chin J Clin Oncol 2009;36:1384-1387.
50.
Xian Z, Liu X, Gai X, Ye J, Huang X, Zhang Z: The curative effect of glandula angularis transposition to treat xerostomia because of the postradiotherapy of nasopharyngeal carcinoma. Int Med Health Guidance News 2009;15:37-39.
51.
Pathak KA, Bhalavat RL, Mistry RC, Deshpande MS, Bhalla V, Desai SB, et al: Upfront submandibular salivary gland transfer in pharyngeal cancers. Oral Oncol 2004;40:960-963.
52.
Al-Qahtani K, Hier MP, Sultanum K, Black MJ: The role of submandibular salivary gland transfer in preventing xerostomia in the chemoradiotherapy patient. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;101:753-756.
53.
Zhang Y, Guo CB, Zhang L, Wang Y, Peng X, Mao C, et al: Prevention of radiation-induced xerostomia by submandibular gland transfer. Head Neck 2012;34:937-942.
54.
Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, et al: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16.
55.
Clark JM: Radiology: an illustrated history. JAMA 1992;268:138.
56.
Coutard H: Roentgen therapy of epitheliomas of the tonsillar region, hypopharynx, and larynx from 1920 to 1926. Am J Roentgenol 1920;28:313-331.
57.
Bergonie J: Sur quelques formes de réactions précoces après des irradiations. Arch Elect Med 1911;19:241-245.
58.
Bruce SD: Radiation-induced xerostomia: how dry is your patient? Clin J Oncol Nurs 2004;8:61-67.
59.
Epstein JB, Robertson M, Emerton S, Phillips N, Stevenson-Moore P: Quality of life and oral function in patients treated with radiation therapy for head and neck cancer. Head Neck 2001;23:389-398.
60.
Rubin P, Casarett G: A direction for clinical radiation pathology. Front Radial Ther Oncol 1972;6:1-16.
61.
Shannon IL, Trodahl JN, Starcke EN: Radiosensitivity of the human parotid gland. Proc Soc Exp Biol Med 1978;157:50-53.
62.
Eneroth CM, Henrikson CO, Jakobsson PA: Pre-irradiation qualities of a parotid gland predicting the grade of functional disturbance by radiotherapy. Acta Otolaryngol 1972;74:436-444.
63.
Makkonen TA, Tenovuo J, Vilja P, Heimdahl A: Changes in the protein composition of whole saliva during radiotherapy in patients with oral or pharyngeal cancer. Oral Surg Oral Med Oral Pathol 1986;62:270-275.
64.
Carlson GW: The salivary glands. Embryology, anatomy, and surgical applications. Surg Clin North Am 2000;80:261-273.
65.
Tucker AS: Salivary gland development. Semin Cell Dev Biol 2007;18:237-244.
66.
Dewhirst MW, Cao Y, Li CY, Moeller B: Exploring the role of HIF-1 in early angiogenesis and response to radiotherapy. Radiother Oncol 2007;83:249-255.
67.
Sas R, Dawes C: The intra-oral distribution of unstimulated and chewing-gum-stimulated parotid saliva. Arch Oral Biol 1997;42:469-474.
68.
Sood AJ, Fox NF, O'Connell BP, Lovelace TL, Nguyen SA, Sharma AK, et al: Salivary gland transfer to prevent radiation-induced xerostomia: a systematic review and meta-analysis. Oral Oncol 2014;50:77-83.
69.
Wu F, Li C: Comment on the article ‘Salivary gland transfer to prevent radiation-induced xerostomia: a systematic review and meta-analysis' by Sood AJ, et al: published in Oral Oncology 50 (2014) 77-83. Oral Oncol 2014;50:e41-e42.
70.
Abraham NS, Byrne CJ, Young JM, Solomon MJ: Meta-analysis of well-designed nonrandomized comparative studies of surgical procedures is as good as randomized controlled trials. J Clin Epidemiol 2010;63:238-245.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.